Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722351 | 0.91 | CRBN (0.64) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL30262839 | 0.91 | CRBN (0.66) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL29223532 | 0.87 | CRBN (0.62) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL23301549 | 0.87 | CRBN (0.70) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL29942811 | 0.87 | CRBN (0.70) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL31722354 | 0.87 | CRBN (0.66) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL29942599 | 0.86 | CRBN (0.67) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL29942622 | 0.85 | CRBN (0.70) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL23300970 | 0.85 | CRBN (0.70) | CRBNDDB1HPGDSALDH1A1CHRM2 | |
| SCHEMBL23301420 | 0.85 | CRBN (0.72) | CRBNDDB1HPGDSALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | CRBN 688/4885DDB1 1230/4885HPGDS 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.